Context Therapeutics (CNTX) Assets Average (2021 - 2026)
Context Therapeutics (CNTX) posted Assets Average of $63.7 million for Q1 2026, down 13.79% sequentially from $73.9 million in Q4 2025, and down 33.36% YoY from $95.5 million in Q1 2025.
Context Therapeutics (CNTX) Assets Average (2021 - 2026) Analysis & Trends
Context Therapeutics has reported Assets Average for 6 years, with the latest figure at $63.7 million in Q1 2026.
- Quarterly Assets Average fell 33.36% year-over-year to $63.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.7 million (down 33.36% YoY) and the FY2025 annual result came in at $83.3 million, up 45.92% from the prior year.
- Assets Average declined to $63.7 million in Q1 2026 per CNTX's latest filing, from $73.9 million in the prior quarter.
- Over five years, Assets Average peaked at $95.5 million in Q1 2025 and troughed at $13.6 million in Q1 2024.
- A 5-year average of $56.0 million and a median of $49.2 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average sank 61.23% in 2024, then jumped 604.76% in 2025.
- Over 5 years, Assets Average stood at $40.0 million in 2022, then plunged by 51.22% to $19.5 million in 2023, then soared by 372.34% to $92.2 million in 2024, then dropped by 19.91% to $73.9 million in 2025, then fell by 13.79% to $63.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $63.7 million, $73.9 million, and $83.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 19.82 Bn |
| 10 | Context Therapeutics | 48.62 Mn | 48.62 Mn | - | 52.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.50 Mn |
| Mar 31, 2026 | 63.68 Mn |
| Dec 31, 2025 | 73.86 Mn |
| Sep 30, 2025 | 83.19 Mn |
| Jun 30, 2025 | 90.06 Mn |
| Mar 31, 2025 | 95.55 Mn |
| Dec 31, 2024 | 92.23 Mn |
| Sep 30, 2024 | 94.52 Mn |
| Jun 30, 2024 | 56.88 Mn |
| Mar 31, 2024 | 13.56 Mn |
| Dec 31, 2023 | 19.53 Mn |
| Sep 30, 2023 | 25.38 Mn |
| Jun 30, 2023 | 29.86 Mn |
| Mar 31, 2023 | 34.97 Mn |
| Dec 31, 2022 | 40.02 Mn |
| Sep 30, 2022 | 43.39 Mn |
| Jun 30, 2022 | 45.86 Mn |
| Mar 31, 2022 | 49.17 Mn |
| Dec 31, 2021 | 26.78 Mn |